凤凰网首页 手机凤凰网

凤凰卫视
  • [亚太] 上证指数 2319.12 (1.00%) 深证成指 9466.14 1.78% 恒生指数 19664.10 -1.06% 台北 7233.69 0.17% 韩国 1964.83 0.39%
  • [亚太] 日经 8841.22 -0.09% 澳大利亚 4348.48 0.45% 新西兰 3294.64 0.40% 印度孟买 17234.00 0.92% 新加坡 2916.26 0.75%
  • [美洲] 道琼斯 12660.50 -0.58% 纳斯达克 2816.55 0.40% 标普500 1316.33 -0.16% 加拿大 12466.50 0.02% 巴西 62904.20 -0.08%
  • [欧洲] 英国富时 5733.45 -1.07% 法国CAC 3318.76 -1.32% 德国DAX 6511.98 -0.43% 俄罗斯 1508.04 -0.44% Stoxx50 2436.62 -0.97%
  • [其他] 纽约原油 99.70 0.00% 纽约黄金 1738.40 0.00% 人民币/美元 6.33 0.00% 美元指数 78.83 0.00% 基金指数 3782.30 1.37%
  • [亚太] 上证指数 2319.12 (1.00%) 深证成指 9466.14 1.78% 恒生指数 19664.10 -1.06% 台北 7233.69 0.17% 韩国 1964.83 0.39%
  • [亚太] 日经 8841.22 -0.09% 澳大利亚 4348.48 0.45% 新西兰 3294.64 0.40% 印度孟买 17234.00 0.92% 新加坡 2916.26 0.75%
  • [美洲] 道琼斯 12660.50 -0.58% 纳斯达克 2816.55 0.40% 标普500 1316.33 -0.16% 加拿大 12466.50 0.02% 巴西 62904.20 -0.08%
  • [欧洲] 英国富时 5733.45 -1.07% 法国CAC 3318.76 -1.32% 德国DAX 6511.98 -0.43% 俄罗斯 1508.04 -0.44% Stoxx50 2436.62 -0.97%
  • [其他] 纽约原油 99.70 0.00% 纽约黄金 1738.40 0.00% 人民币/美元 6.33 0.00% 美元指数 78.83 0.00% 基金指数 3782.30 1.37%
免费注册
莱茵生物(002166)公告正文

莱茵生物:2012年半年度报告摘要

公告日期 2012-08-29
股票简称:莱茵生物 股票代码:002166
                                                             桂林莱茵生物科技股份有限公司 2012 年半年度报告摘要
    证券代码:002166                            证券简称:莱茵生物                                 公告编号:2012-037
                                   2012 年半年度报告摘要
                                            一、重要提示
    本公司董事会、监事会及董事、监事、高级管理人员保证本报告所载资料不存在任何虚假记载、误导性陈述或者重大遗漏,并对其内容的真实性、准确性和完整性承担个别及连带责任。
    所有董事均已出席了审议本次半年报的董事会会议。
    公司半年度财务报告未经会计师事务所审计。
    公司负责人姚新德、主管会计工作负责人周庆伟及会计机构负责人(会计主管人员)张为鹏声明:保证半年度报告中财务报告的真实、完整。
                                       二、公司基本情况(一)基本情况简介
    A 股简称                           莱茵生物
    A 股代码                           002166
    上市证券交易所                     深圳证券交易所
                                                  董事会秘书                              证券事务代表
    姓名                               罗华阳                                 唐春龙
    联系地址                           桂林市临桂县西城南路秧塘工业园         桂林市临桂县西城南路秧塘工业园
    电话                               0773-3568817                           0773-3568817
    传真                               0773-3568872                           0773-3568872
    电子信箱                           luo.huayang@layn.com.cn                tang.chunlong@layn.com.cn(二)主要财务数据和指标1、主要会计数据和财务指标以前报告期财务报表是否发生了追溯调整□ 是 √ 否
                                                                                          本报告期末比上年度期末
                                            本报告期末               上年度期末
                                                                                                  增减(%)
    总资产(元)                                    926,908,614.08           926,121,569.54                     0.08%
    归属于上市公司股东的所有者权益(元)            211,534,401.09           229,240,891.08                    -7.72%
                                                             桂林莱茵生物科技股份有限公司 2012 年半年度报告摘要
    股本(股)                                    129,533,760.00              129,533,760.00                       0%归属于上市公司股东的每股净资产(元/
                                                          1.63                       1.77                   -7.91%股)
    资产负债率(%)                                       77.16%                      75.22%                     1.94%
                                                                                            本报告期比上年同期增减
                                       报告期(1-6 月)                上年同期
                                                                                                      (%)
    营业总收入(元)                              105,611,043.05               44,806,227.33                   135.71%
    营业利润(元)                                -19,911,058.60              -25,285,459.85                    21.25%
    利润总额(元)                                -17,802,358.47              -22,634,686.19                    21.35%
    归属于上市公司股东的净利润(元)              -17,801,699.85              -22,630,704.30                    21.34%归属于上市公司股东的扣除非经常性损
                                              -19,959,365.45              -25,161,281.02                    20.67%益的净利润(元)
    基本每股收益(元/股)                                   -0.14                       -0.17                   17.65%
    稀释每股收益(元/股)                                   -0.14                       -0.17                   17.65%
    加权平均净资产收益率(%)                             -8.08%                      -10.5%                     2.42%扣除非经常性损益后的加权平均净资产
                                                      -9.06%                      -11.67%                    2.61%收益率(%)
    经营活动产生的现金流量净额(元)              -53,151,075.61                -7,394,841.00                 -618.76%每股经营活动产生的现金流量净额(元/
                                                        -0.41                       -0.06                 -583.33%股)报告期末公司前主要会计数据和财务指标的说明(如有追溯调整,请填写调整说明)2、非经常性损益项目√ 适用 □ 不适用
                    非经常性损益项目               年初到报告期末金额(元)                    说明非流动资产处置损益越权审批或无正式批准文件的税收返还、减免计入当期损益的政府补助(与企业业务密切相关,按照
                                                                 1,311,473.00国家统一标准定额或定量享受的政府补助除外)
    计入当期损益的对非金融企业收取的资金占用费                        348,833.34企业取得子公司、联营企业及合营企业的投资成本小于取得投资时应享有被投资单位可辨认净资产公允价值产生的收益非货币性资产交换损益委托他人投资或管理资产的损益因不可抗力因素,如遭受自然灾害而计提的各项资产减值准备债务重组损益企业重组费用,如安置职工的支出、整合费用等交易价格显失公允的交易产生的超过公允价值部分的损益同一控制下企业合并产生的子公司期初至合并日的当期净损益与公司正常经营业务无关的或有事项产生的损益除同公司正常经营业务相关的有效套期保值业务外,持有交易性金融资产、交易性金融负债产生的公允价值变
                                                               桂林莱茵生物科技股份有限公司 2012 年半年度报告摘要动损益,以及处置交易性金融资产、交易性金融负债和可供出售金融资产取得的投资收益单独进行减值测试的应收款项减值准备转回对外委托贷款取得的损益采用公允价值模式进行后续计量的投资性房地产公允价值变动产生的损益根据税收、会计等法律、法规的要求对当期损益进行一次性调整对当期损益的影响受托经营取得的托管费收入
    除上述各项之外的其他营业外收入和支出                                797,227.13其他符合非经常性损益定义的损益项目少数股东权益影响额
    所得税影响额                                                       -299,867.87
    合计                                                              2,157,665.60                   --3、同时按照国际会计准则与按中国会计准则披露的财务报告中净利润和净资产差异情况□ 适用 √ 不适用4、同时按照境外会计准则与按中国会计准则披露的财务报告中净利润和净资产差异情况□ 适用 √ 不适用
                                     三、股本变动及股东情况(一)股本变动情况表√ 适用 □ 不适用
                            本次变动前                  本次变动增减(+,-)                         本次变动后
                                                                 公积金转
                           数量      比例(%) 发行新股   送股                     其他    小计         数量    比例(%)
                                                                   股
                         48,814,71                                          -14,383,50 -14,383,50 34,431,20
    一、有限售条件股份                    37.68%                                                                   26.58%
                                 1                                                   4          4         71、国家持股2、国有法人持股3、其他内资持股其中:境内法人持股境内自然人持股4、外资持股其中:境外法人持股境外自然人持股
                         48,814,71                                          -14,383,50 -14,383,50 34,431,20
    5.高管股份                            37.68%                                                                   26.58%
                                 1                                                   4          4         7
                                                                   桂林莱茵生物科技股份有限公司 2012 年半年度报告摘要
                             80,719,04                                             14,383,50 14,383,50 95,102,55
    二、无限售条件股份                        62.32%                                                                         73.42%
                                     9                                                     4         4         3
                             80,719,04                                             14,383,50 14,383,50 95,102,55
    1、人民币普通股                           62.32%                                                                         73.42%
                                     9                                                     4         4         32、境内上市的外资股3、境外上市的外资股4、其他
                             129,533,7                                                                    129,533,7
    三、股份总数                                100%                                                                          100%
                                 60.00                                                                        60.00(二)前 10 名股东、前 10 名无限售条件股东/流通股股东持股情况表前 10 名股东、前 10 名无限售条件股东持股情况表
    股东总数                                                                                                                 41,831前十名股东持股情况
                                                  持股比例                    持有有限售条         质押或冻结情况
    股东名称(全称)             股东性质                     持股总数
                                                    (%)                         件股份数量     股份状态           数量
                   秦本军          境内自然人      29.81%        38,613,504      24,230,000 质押                      24,230,000
                   姚新德          境内自然人       10.5%        13,601,609      10,201,207 质押                       7,730,000
                   蒋安明          境内自然人       3.34%         4,331,576
                   黎科弟          境内自然人       0.23%          302,500
                   经伟庆          境内自然人       0.21%          268,200
                   王龙花          境内自然人       0.17%          216,000
                      刘蕊         境内自然人       0.13%          170,500
                   李国华          境内自然人       0.12%          156,880
                   陈巧云          境内自然人       0.12%          153,279
                   郭天晓          境内自然人        0.11%         144,900前十名无限售条件股东持股情况
                                                                                             股份种类及数量
                  股东名称                         持有无限售条件股份数量
                                                                                   种类                    数量
                                         秦本军                  14,383,504 A 股                                      14,383,504
                                         蒋安明                   4,331,576 A 股                                       4,331,576
                                         姚新德                   3,400,402 A 股                                       3,400,402
                                         黎科弟                    302,500 A 股                                         302,500
                                         经伟庆                    268,200 A 股                                         268,200
                                         王龙花                    216,000 A 股                                         216,000
                                           刘蕊                    170,500 A 股                                         170,500
                                         李国华                    156,880 A 股                                         156,880
                                         陈巧云                    153,279 A 股                                         153,279
                                         郭天晓                    144,900 A 股                                         144,900
                                         公司股东秦本军先生与蒋安明先生为兄弟关系,属于一致行动人,除上述关上述股东关联关系或(及)一致行动人的说明 联关系以外,公司前 3 大股东之间不存在关联关系或一致行动,其他股东之
                                         间关系不详。
                                                                   桂林莱茵生物科技股份有限公司 2012 年半年度报告摘要(三)控股股东及实际控制人变更情况□ 适用 √ 不适用
                              四、董事、监事和高级管理人员情况(一)董事、监事和高级管理人员持股变动
                                                                         其中:持有限 期末持有股
                             期初持股数 本期增持股 本期减持股 期末持股数
    姓名           职务                                                 制性股票数 票期权数量              变动原因
                               (股)   份数量(股)份数量(股) (股)
                                                                           量(股)     (股)
    姚新德        董事长           13,601,609                             13,601,609                        -
    杨晓涛        董事                     0                                      0                         -
    廖靖军        董事;总经理              0                                      0                         -
    孙步祥        董事                     0                                      0                         -
              董事;副总经
    蒋小三                                 0                                      0                         -
              理
    王若晨        独立董事                 0                                      0                         -
    刘红玉        独立董事                 0                                      0                         -
    杨建军        独立董事                 0                                      0                         -
    李元元        监事                     0                                      0                         -
    唐友铖        监事                     0                                      0                         -
    李   杰       监事                     0                                      0                         -
              董事会秘书;
    罗华阳                                 0                                      0                         -
              副总经理
    周庆伟        财务总监                 0                                      0                         -
    谢永富        副总经理                 0                                      0                         -
    易水平        副总经理                 0                                      0                         -
                                               五、董事会报告(一)主营业务分行业、产品情况表
                                                                                                              单位:元
                                                  主营业务分行业情况
                                                                      营业收入比上年 营业成本比上年 毛利率比上年同
    分行业            营业收入        营业成本        毛利率(%)
                                                                      同期增减(%) 同期增减(%) 期增减(%)
    植物提取行业           82,212,796.90   72,285,603.61        12.07%            83.94%         107.36%           -9.93%
    BT 项目                22,553,455.30   17,679,506.44        21.61%
                                                   主营业务产品情况
                                                                  桂林莱茵生物科技股份有限公司 2012 年半年度报告摘要
                                                                     营业收入比上年 营业成本比上年 毛利率比上年同
       分产品          营业收入       营业成本        毛利率(%)
                                                                     同期增减(%) 同期增减(%) 期增减(%)
    植物提取产品          82,212,796.90   72,285,603.61        12.07%             83.94%        107.36%           -9.93%
    BT 项目               22,553,455.30   17,679,506.44        21.61%毛利率比上年同期增减幅度较大的原因说明植物提取业务毛利率下滑,主要系因为报告期内公司销售的部分产品前期库存成本较高所致。BT项目为新增业务。(二)主营业务分地区情况
                                                                                                             单位:元
                    地区                              营业收入                     营业收入比上年同期增减(%)
    国内                                                               40,323,311.28                             214.23%
    国外                                                               64,442,940.92                             102.25%(三)主营业务及其结构发生重大变化的原因说明√ 适用 □ 不适用
    报告期内,公司主营业务未发生重大变化,公司专注于植物提取业务,为以罗汉果、甜叶菊、红景天、荔枝皮等植物提取物为公司主打产品。新增主营业务系全资子公司莱茵投资的BT项目开工建设,并有子项目完工,取得收益。(四)主营业务盈利能力(毛利率)与上年相比发生重大变化的原因说明√ 适用 □ 不适用
    植物提取业务毛利率下滑,主要系因为报告期内公司销售的部分产品前期库存成本较高所致。BT项目为新增业务。(五)利润构成与上年相比发生重大变化的原因分析□ 适用 √ 不适用(六)募集资金使用情况1、募集资金使用情况对照表□ 适用 √ 不适用2、变更募集资金投资项目情况表□ 适用 √ 不适用(七)董事会下半年的经营计划修改计划□ 适用 √ 不适用(八)对 2012 年 1-9 月经营业绩的预计2012 年 1-9 月预计的经营业绩情况:业绩亏损业绩亏损
    2012 年 1-9 月净利润亏损(万元)                           2000                    至                 2500
                                                           桂林莱茵生物科技股份有限公司 2012 年半年度报告摘要2011 年 1-9 月归属于上市公司股东的净利润
                                                                                                -31,196,376.52(元)
                                           公司预计 1-9 月份主营的植物提取业务销售情况与上年同期相比会有大幅
    业绩变动的原因说明                         改善,但毛利率未能得到有效提升,同时,为满足莱茵投资的 BT 项目资
                                           金需求,提升项目运营能力,公司的财务费用支出较高。(九)董事会对会计师事务所本报告期“非标准审计报告”的说明□ 适用 √ 不适用(十)公司董事会对会计师事务所上年度“非标准审计报告”涉及事项的变化及处理情况的说明□ 适用 √ 不适用
                                            六、重要事项(一)收购、出售资产及资产重组1、收购资产□ 适用 √ 不适用收购资产情况说明2、出售资产情况□ 适用 √ 不适用出售资产情况说明3、自资产重组报告书或收购出售资产公告刊登后,该事项的进展情况及对报告期经营成果与财务状况的影响□ 适用 √ 不适用(二)担保事项√ 适用 □ 不适用
                                                                                                   单位:万元
                                   公司对外担保情况(不包括对子公司的担保)
                                                                                                    是否为关
                     担保额度            实际发生日期
                                                                                           是否履行 联方担保
    担保对象名称      相关公告   担保额度 (协议签署 实际担保金额     担保类型     担保期
                                                                                             完毕     (是或
                     披露日期                日)
                                                                                                      否)
                                                                  桂林莱茵生物科技股份有限公司 2012 年半年度报告摘要
    报告期内审批的对外担保额度                                   报告期内对外担保实际发生
                                                         0                                                          0
    合计(A1)                                                   额合计(A2)
    报告期末已审批的对外担保额                                   报告期末实际对外担保余额
                                                         0                                                          0
    度合计(A3)                                                 合计(A4)
                                            公司对子公司的担保情况
                                                                                                            是否为关
                    担保额度            实际发生日期
                                                                                                   是否履行 联方担保
    担保对象名称      相关公告   担保额度 (协议签署 实际担保金额            担保类型       担保期
                                                                                                     完毕     (是或
                    披露日期                日)
                                                                                                              否)
                                                                                        借款合同债
    桂林莱茵生物技术 2011 年 08              2011 年 09 月                                  务履行期限
                                   6,000                            4,000 保证                     否      否
    有限公司         月 20 日                06 日                                          届满之日起
                                                                                        2年
                                                                                        借款合同债
    桂林莱茵生物技术 2010 年 02              2010 年 02 月                                  务履行期限
                                   6,000                            5,000 保证                     否      否
    有限公司         月 03 日                25 日                                          届满之日起
                                                                                        2年
    报告期内审批对子公司担保额                                   报告期内对子公司担保实际
                                                         0                                                       4,000
    度合计(B1)                                                 发生额合计(B2)
    报告期末已审批的对子公司担                                   报告期末对子公司实际担保
                                                 12,000                                                          9,000
    保额度合计(B3)                                             余额合计(B4)公司担保总额(即前两大项的合计)
    报告期内审批担保额度合计                                     报告期内担保实际发生额合
                                                         0                                                       4,000
    (A1+B1)                                                    计(A2+B2)
    报告期末已审批的担保额度合                                   报告期末实际担保余额合计
                                                 12,000                                                          9,000
    计(A3+B3)                                                  (A4+B4)
    实际担保总额(即 A4+B4)占公司净资产的比例                                                                      0.4255其中:
    为股东、实际控制人及其关联方提供担保的金额(C)                                                                     0直接或间接为资产负债率超过 70%的被担保对象提供的债
                                                                                                                    0务担保金额(D)
    担保总额超过净资产 50%部分的金额(E)                                                                               0
    上述三项担保金额合计(C+D+E)                                                                                       0
    未到期担保可能承担连带清偿责任说明                           不适用。
    违反规定程序对外提供担保的说明                               不适用。(三)非经营性关联债权债务往来是否存在非经营性关联债权债务往来□ 是 √ 否(四)重大诉讼仲裁事项√ 适用 □ 不适用
    2011年5月,我公司就与西昌富万利买卖合同纠纷一案向临桂县人民法院提起诉讼,经受理后,2011年6月,西昌富万利提出管辖异议并上诉至桂林市中级人民法院,2011年8月,桂林市中级人民法院裁定驳回上诉。临桂县人民法院经审理后于2011年12月19日做出判决,判决西昌富万利返还我公司货款2,413,000元,并赔偿经济损失845,943.04元,我公司返还对方货物。截至本报告发布日,对方尚未执行该判决,我公司向法院申请强制执行,已收回款项34万元整。
    本公司在报告期内不存在其他重大诉讼、仲裁事项。
                                                             桂林莱茵生物科技股份有限公司 2012 年半年度报告摘要(五)其他重大事项及其影响和解决方案的分析说明□ 适用 √ 不适用1、证券投资情况□ 适用 √ 不适用证券投资情况的说明2、持有其他上市公司股权情况□ 适用 √ 不适用持有其他上市公司股权情况的说明3、报告期内资金被占用情况及清欠进展情况□ 适用 √ 不适用截止报告期末,上市公司未完成非经营性资金占用的清欠工作的,董事会提出的责任追究方案□ 适用 √ 不适用4、承诺事项履行情况上市公司及其董事、监事和高级管理人员、公司持股 5%以上股东及其实际控制人等有关方在报告期内或持续到报告期内的以下承诺事项□ 适用 √ 不适用5、董事会本次利润分配或资本公积金转增预案□ 适用 √ 不适用6、其他综合收益细目
                                                                                                      单位:元
                           项目                                     本期发生额               上期发生额1.可供出售金融资产产生的利得(损失)金额减:可供出售金融资产产生的所得税影响前期计入其他综合收益当期转入损益的净额小计2.按照权益法核算的在被投资单位其他综合收益中所享有的份额减:按照权益法核算的在被投资单位其他综合收益中所享有的份额产生的所得税影响前期计入其他综合收益当期转入损益的净额小计3.现金流量套期工具产生的利得(或损失)金额减:现金流量套期工具产生的所得税影响前期计入其他综合收益当期转入损益的净额
                                                           桂林莱茵生物科技股份有限公司 2012 年半年度报告摘要转为被套期项目初始确认金额的调整额小计
    4.外币财务报表折算差额                                                           -62,938.85                 -22,010.01减:处置境外经营当期转入损益的净额
    小计                                                                             -62,938.85                 -22,010.015.其他减:由其他计入其他综合收益产生的所得税影响前期其他计入其他综合收益当期转入损益的净额小计
    合计                                                                             -62,938.85                 -22,010.01(六)报告期接待调研、沟通、采访等活动登记表
                                                                                              谈论的主要内容及提供
       接待时间          接待地点          接待方式      接待对象类型            接待对象
                                                                                                      的资料
                                             七、财务报告(一)审计意见半年报是否经过审计□ 是 √ 否(二)财务报表是否需要合并报表:√ 是 □ 否1、合并资产负债表编制单位: 桂林莱茵生物科技股份有限公司
                                                                                                             单位: 元
                  项目              附注              期末余额                                期初余额
    流动资产:
       货币资金                                              108,967,281.96                              74,764,663.71
       结算备付金
       拆出资金
       交易性金融资产
       应收票据
       应收账款                                                  71,881,001.25                           53,348,168.95
       预付款项                                                  29,706,688.71                           67,598,397.81
       应收保费
                           桂林莱茵生物科技股份有限公司 2012 年半年度报告摘要
    应收分保账款
    应收分保合同准备金
    应收利息                     7,044,694.45                      6,695,861.11
    应收股利
    其他应收款                  64,237,032.09                     59,027,629.42
    买入返售金融资产
    存货                       439,970,488.90                    447,356,571.39
    一年内到期的非流动资产
    其他流动资产                  102,910.83
    流动资产合计                 721,910,098.19                    708,791,292.39非流动资产:
    发放委托贷款及垫款
    可供出售金融资产
    持有至到期投资
    长期应收款
    长期股权投资                26,030,000.00                     26,030,000.00
    投资性房地产
    固定资产                   158,927,133.99                    164,786,670.39
    在建工程                      100,000.00
    工程物资
    固定资产清理                -6,300,000.00
    生产性生物资产
    油气资产
    无形资产                    24,734,823.00                     25,007,047.86
    开发支出
    商誉
    长期待摊费用
    递延所得税资产               1,506,558.90                      1,506,558.90
    其他非流动资产
    非流动资产合计               204,998,515.89                    217,330,277.15
    资产总计                     926,908,614.08                    926,121,569.54流动负债:
    短期借款                   303,645,772.21                    334,700,000.00
    向中央银行借款
    吸收存款及同业存放
    拆入资金
    交易性金融负债
    应付票据                                                      28,000,000.00
    应付账款                   139,523,373.90                    219,533,351.50
    预收款项                     1,714,019.29                       841,585.77
    卖出回购金融资产款
    应付手续费及佣金
    应付职工薪酬                  453,268.87                       1,146,398.08
                                                            桂林莱茵生物科技股份有限公司 2012 年半年度报告摘要
    应交税费                                                      -4,345,518.53                      -729,993.42
    应付利息                                                         34,563.56                       807,736.42
    应付股利
    其他应付款                                                102,062,893.94                       51,521,580.86
    应付分保账款
    保险合同准备金
    代理买卖证券款
    代理承销证券款
    一年内到期的非流动负债                                        20,626,566.00                    21,253,132.00
    其他流动负债
    流动负债合计                                                563,714,939.24                    657,073,791.21
    非流动负债:
    长期借款                                                  140,000,000.00                       30,000,000.00
    应付债券
    长期应付款
    专项应付款
    预计负债
    递延所得税负债
    其他非流动负债                                                11,447,534.00                     9,572,534.00
    非流动负债合计                                              151,447,534.00                       39,572,534.00
    负债合计                                                    715,162,473.24                    696,646,325.21
    所有者权益(或股东权益):
    实收资本(或股本)                                        129,533,760.00                    129,533,760.00
    资本公积                                                      83,217,530.86                    83,217,530.86
    减:库存股
    专项储备
    盈余公积                                                       8,834,943.24                     8,834,943.24
    一般风险准备
    未分配利润                                                    -9,988,894.16                     7,812,805.69
    外币报表折算差额                                                 -62,938.85                      -158,148.71
    归属于母公司所有者权益合计                                       211,534,401.09                 229,240,891.08
    少数股东权益                                                    211,739.75                       234,353.25
    所有者权益(或股东权益)合计                                     211,746,140.84                 229,475,244.33负债和所有者权益(或股东权益)
                                                              926,908,614.08                    926,121,569.54总计
    法定代表人:姚新德                      主管会计工作负责人:周庆伟                    会计机构负责人:张为鹏2、母公司资产负债表
                                                                                                       单位: 元
               项目              附注                 期末余额                          期初余额
    流动资产:
    货币资金                                                  100,782,674.94                       60,736,523.55
                           桂林莱茵生物科技股份有限公司 2012 年半年度报告摘要
    交易性金融资产
    应收票据
    应收账款                    56,243,796.00                     57,981,918.93
    预付款项                     5,705,281.51                      2,764,333.71
    应收利息
    应收股利
    其他应收款                  55,122,470.72                     51,194,635.33
    存货                       142,489,222.03                    155,229,954.82
    一年内到期的非流动资产
    其他流动资产                  102,910.83
    流动资产合计                 360,446,356.03                    327,907,366.34非流动资产:
    可供出售金融资产
    持有至到期投资
    长期应收款
    长期股权投资               500,184,924.59                    500,184,924.59
    投资性房地产
    固定资产                    12,368,204.33                     14,325,082.56
    在建工程
    工程物资
    固定资产清理                -6,300,000.00
    生产性生物资产
    油气资产
    无形资产                      753,600.66                        743,715.13
    开发支出
    商誉
    长期待摊费用
    递延所得税资产               2,278,239.89                      2,278,239.89
    其他非流动资产
    非流动资产合计               509,284,969.47                    517,531,962.17
    资产总计                     869,731,325.50                    845,439,328.51流动负债:
    短期借款                   263,645,772.21                    324,700,000.00
    交易性金融负债
    应付票据
    应付账款                    57,132,006.51                     27,986,062.82
    预收款项                     1,714,019.29                       841,585.77
    应付职工薪酬                  376,393.53                        880,923.98
    应交税费                    -1,585,901.24                      3,115,425.54
    应付利息                        34,563.56                       690,494.75
    应付股利
    其他应付款                 181,691,986.07                    218,429,390.13
    一年内到期的非流动负债        301,566.00                        603,132.00
                                             桂林莱茵生物科技股份有限公司 2012 年半年度报告摘要
       其他流动负债
    流动负债合计                                 503,310,405.93                    577,247,014.99
    非流动负债:
       长期借款                                110,000,000.00
       应付债券
       长期应付款
       专项应付款
       预计负债
       递延所得税负债
       其他非流动负债                               5,085,034.00                     4,697,534.00
    非流动负债合计                               115,085,034.00                        4,697,534.00
    负债合计                                     618,395,439.93                    581,944,548.99
    所有者权益(或股东权益):
       实收资本(或股本)                      129,533,760.00                    129,533,760.00
       资本公积                                    85,883,914.34                    85,883,914.34
       减:库存股
       专项储备
       盈余公积                                     8,834,943.24                     8,834,943.24
       未分配利润                                  27,083,267.99                    39,242,161.94
       外币报表折算差额
    所有者权益(或股东权益)合计                 251,335,885.57                    263,494,779.52
    负债和所有者权益(或股东权
                                               869,731,325.50                    845,439,328.51益)总计3、合并利润表
                                                                                        单位: 元
                  项目           附注   本期金额                         上期金额
    一、营业总收入                                 105,611,043.05                       44,806,227.33
       其中:营业收入                          105,611,043.05                       44,806,227.33
            利息收入
            已赚保费
            手续费及佣金收入
    二、营业总成本                                 125,450,495.03                       69,426,412.78
       其中:营业成本                              90,225,321.44                    34,965,941.93
            利息支出
            手续费及佣金支出
            退保金
            赔付支出净额
            提取保险合同准备金净额
            保单红利支出
            分保费用
            营业税金及附加                          1,218,297.00                         3,551.69
                                                                   桂林莱茵生物科技股份有限公司 2012 年半年度报告摘要
             销售费用                                                  4,950,496.29                        4,847,856.34
             管理费用                                                 14,947,187.82                       15,145,694.29
             财务费用                                                 13,205,615.34                       12,930,147.94
             资产减值损失                                                903,577.14                        1,533,220.59
    加      :公允价值变动收益(损失以“-”号填列)
             投资收益(损失以“-”
                                                                         161,994.00号填列)
          其中:对联营企业和合营企业的投资收益
             汇兑收益(损失以“-”
                                                                        -233,600.62                         -665,274.40号填列)
    三、营业利润(亏损以“-”号填列)                                    -19,911,058.60                      -25,285,459.85
       加   :营业外收入                                               2,314,063.87                        2,656,511.01
       减   :营业外支出                                                 205,363.74                            5,737.35
             其中:非流动资产处置损失四、利润总额(亏损总额以“-”号
                                                                      -17,802,358.47                      -22,634,686.19填列)
       减:所得税费用                                                     21,954.88
    五、净利润(净亏损以“-”号填列)                                    -17,824,313.35                      -22,634,686.19
    其中:被合并方在合并前实现的净利润
       归属于母公司所有者的净利
                                                                      -17,801,699.85                      -22,630,704.30润
       少数股东损益                                                       -22,613.50                           -3,981.89
    六、每股收益:                                                --                                  --
       (一)基本每股收益                                                      -0.14                               -0.17
       (二)稀释每股收益                                                      -0.14                               -0.17
    七、其他综合收益                                                          -62,938.85                          -22,010.01
    八、综合收益总额                                                      -17,887,252.20                      -22,656,696.20
    归属于母公司所有者的综合
                                                                      -17,864,638.70                      -22,652,714.31收益总额
       归属于少数股东的综合收益
                                                                          -22,613.50                           -3,981.89总额本期发生同一控制下企业合并的,被合并方在合并前实现的净利润为:0 元。
    法定代表人:姚新德                           主管会计工作负责人:周庆伟                      会计机构负责人:张为鹏4、母公司利润表
                                                                                                              单位: 元
                项目                  附注                 本期金额                            上期金额
    一、营业收入                                                          75,416,488.90                       48,191,726.62
       减:营业成本                                                   65,070,937.54                       38,365,950.19
            营业税金及附加                                               518,255.16
                                                     桂林莱茵生物科技股份有限公司 2012 年半年度报告摘要
         销售费用                                        3,473,622.14                      3,556,380.80
         管理费用                                        8,971,362.10                      8,606,928.56
         财务费用                                       10,913,410.96                     11,921,954.08
         资产减值损失                                      537,481.78                      1,490,085.18
      加:公允价值变动收益(损失以“-”号填列)
         投资收益(损失以“-”号
                                                           161,994.00填列)
        其中:对联营企业和合营企业的投资收益
    二、营业利润(亏损以“-”号填列)                     -13,906,586.78                     -15,749,572.19
    加:营业外收入                                      1,417,730.26                      2,011,488.12
    减:营业外支出                                        204,163.74                          5,737.35
         其中:非流动资产处置损失三、利润总额(亏损总额以“-”号
                                                       -12,693,020.26                     -13,743,821.42填列)
    减:所得税费用                                       -534,126.31
    四、净利润(净亏损以“-”号填列)                     -12,158,893.95                     -13,743,821.42
    五、每股收益:                                  --                                  --
    (一)基本每股收益                                         -0.09                              -0.11
    (二)稀释每股收益                                         -0.09                              -0.11六、其他综合收益
    七、综合收益总额                                       -12,158,893.95                     -13,743,821.425、合并现金流量表
                                                                                              单位: 元
                 项目                本期金额                                  上期金额一、经营活动产生的现金流量:
    销售商品、提供劳务收到的现金                    87,246,986.18                        49,378,104.82
    客户存款和同业存放款项净增加额
    向中央银行借款净增加额
    向其他金融机构拆入资金净增加额
    收到原保险合同保费取得的现金
    收到再保险业务现金净额
    保户储金及投资款净增加额
    处置交易性金融资产净增加额
    收取利息、手续费及佣金的现金
    拆入资金净增加额
    回购业务资金净增加额
    收到的税费返还                                   2,048,339.40                         4,331,845.31
    收到其他与经营活动有关的现金                    53,511,763.98                         4,570,485.62
                                     桂林莱茵生物科技股份有限公司 2012 年半年度报告摘要
    经营活动现金流入小计                142,807,089.56                        58,280,435.75
    购买商品、接受劳务支付的现金   156,882,149.70                        36,063,319.10
    客户贷款及垫款净增加额
    存放中央银行和同业款项净增加额
    支付原保险合同赔付款项的现金
    支付利息、手续费及佣金的现金
    支付保单红利的现金
    支付给职工以及为职工支付的现
                                     11,030,521.39                         9,241,552.49金
    支付的各项税费                   5,891,819.63                         1,335,303.43
    支付其他与经营活动有关的现金    22,153,674.45                        19,035,101.73
    经营活动现金流出小计                195,958,165.17                        65,675,276.75
    经营活动产生的现金流量净额          -53,151,075.61                        -7,394,841.00二、投资活动产生的现金流量:
    收回投资收到的现金
    取得投资收益所收到的现金          161,994.00
    处置固定资产、无形资产和其他
                                      5,928,250.00长期资产收回的现金净额
    处置子公司及其他营业单位收到的现金净额
    收到其他与投资活动有关的现金
    投资活动现金流入小计                  6,090,244.00
    购建固定资产、无形资产和其他
                                      4,849,442.40                         6,907,549.68长期资产支付的现金
    投资支付的现金
    质押贷款净增加额
    取得子公司及其他营业单位支付的现金净额
    支付其他与投资活动有关的现金                                        200,000,000.00
    投资活动现金流出小计                  4,849,442.40                       206,907,549.68
    投资活动产生的现金流量净额            1,240,801.60                      -206,907,549.68三、筹资活动产生的现金流量:
    吸收投资收到的现金
    其中:子公司吸收少数股东投资收到的现金
    取得借款收到的现金             199,908,659.09                       235,000,000.00
    发行债券收到的现金
    收到其他与筹资活动有关的现金    84,000,000.00                        37,500,000.00
    筹资活动现金流入小计                283,908,659.09                       272,500,000.00
    偿还债务支付的现金             121,000,000.00                        50,000,000.00
    分配股利、利润或偿付利息支付
                                     13,949,021.27                         6,300,113.67的现金
    其中:子公司支付给少数股东的股利、利润
                                                桂林莱茵生物科技股份有限公司 2012 年半年度报告摘要
    支付其他与筹资活动有关的现金               62,791,759.58                         91,627,925.00
    筹资活动现金流出小计                           197,740,780.85                        147,928,038.67
    筹资活动产生的现金流量净额                      86,167,878.24                        124,571,961.33四、汇率变动对现金及现金等价物的
                                                   -54,985.98                             -63,137.08影响
    五、现金及现金等价物净增加额                    34,202,618.25                         -89,793,566.43
    加:期初现金及现金等价物余额               74,764,663.71                        100,027,962.67
    六、期末现金及现金等价物余额                   108,967,281.96                         10,234,396.246、母公司现金流量表
                                                                                          单位: 元
               项目                 本期金额                              上期金额一、经营活动产生的现金流量:
    销售商品、提供劳务收到的现金               79,622,714.81                         47,521,225.86
    收到的税费返还                              2,048,339.40                           4,331,845.31
    收到其他与经营活动有关的现金                2,173,661.84                           3,403,751.88
    经营活动现金流入小计                            83,844,716.05                         55,256,823.05
    购买商品、接受劳务支付的现金               62,800,743.67                         45,679,314.66
    支付给职工以及为职工支付的现
                                                 5,592,296.07                           5,188,155.76金
    支付的各项税费                              4,584,664.19                            468,066.71
    支付其他与经营活动有关的现金                9,493,065.12                         10,883,656.37
    经营活动现金流出小计                            82,470,769.05                         62,219,193.50
    经营活动产生的现金流量净额                       1,373,947.00                          -6,962,370.45二、投资活动产生的现金流量:
    收回投资收到的现金
    取得投资收益所收到的现金                     161,994.00
    处置固定资产、无形资产和其他
                                                 5,928,250.00长期资产收回的现金净额
    处置子公司及其他营业单位收到的现金净额
    收到其他与投资活动有关的现金
    投资活动现金流入小计                             6,090,244.00
    购建固定资产、无形资产和其他
                                                  232,570.00                              72,396.05长期资产支付的现金
    投资支付的现金                                                                  201,963,490.00
    取得子公司及其他营业单位支付的现金净额
    支付其他与投资活动有关的现金
    投资活动现金流出小计                              232,570.00                         202,035,886.05
    投资活动产生的现金流量净额                       5,857,674.00                        -202,035,886.05三、筹资活动产生的现金流量:
    吸收投资收到的现金
    取得借款收到的现金                        159,908,659.09                        235,000,000.00
                                                            桂林莱茵生物科技股份有限公司 2012 年半年度报告摘要
    发行债券收到的现金
    收到其他与筹资活动有关的现金                            44,000,000.00                               36,500,000.00
    筹资活动现金流入小计                                       203,908,659.09                              271,500,000.00
    偿还债务支付的现金                                     111,000,000.00                               50,000,000.00
    分配股利、利润或偿付利息支付
                                                            11,246,840.72                                 4,580,708.67的现金
    支付其他与筹资活动有关的现金                            48,791,759.58                              102,607,925.00
    筹资活动现金流出小计                                       171,038,600.30                              157,188,633.67
    筹资活动产生的现金流量净额                                  32,870,058.79                              114,311,366.33四、汇率变动对现金及现金等价物的
                                                               -55,528.40                                   -41,127.07影响
    五、现金及现金等价物净增加额                                40,046,151.39                               -94,728,017.24
    加:期初现金及现金等价物余额                            60,736,523.55                               97,532,456.19
    六、期末现金及现金等价物余额                               100,782,674.94                                 2,804,438.957、合并所有者权益变动表本期金额
                                                                                                             单位: 元
                                                                 本期金额
                                                归属于母公司所有者权益
             项目            实收资                                                               少数股东 所有者权
                                    资本公 减:库存 专项储 盈余公 一般风 未分配                     权益     益合计
                             本(或                                                     其他
                                      积       股     备     积   险准备 利润
                             股本)
                             129,533 83,217,5               8,834,9         7,812,80 -158,14 234,353.2 229,475,24一、上年年末余额
                              ,760.00   30.86                 43.24             5.69    8.71         5       4.33
    加:会计政策变更
           前期差错更正
           其他
                             129,533 83,217,5               8,834,9         7,812,80 -158,14 234,353.2 229,475,24二、本年年初余额
                              ,760.00   30.86                 43.24             5.69    8.71         5       4.33
    三、本期增减变动金额(减少                                                  -17,801, 95,209.8 -22,613.5 -17,729,10
    以“-”号填列)                                                              699.85        6         0       3.49
                                                                            -17,801,              -22,613.5 -17,824,31(一)净利润
                                                                              699.85                      0       3.35
                                                                                       95,209.8
    (二)其他综合收益                                                                                          95,209.86
                                                                                              6
                                                                            -17,801, 95,209.8 -22,613.5 -17,729,10上述(一)和(二)小计
                                                                              699.85        6         0       3.49(三)所有者投入和减少资本1.所有者投入资本2.股份支付计入所有者权益的金额3.其他(四)利润分配1.提取盈余公积2.提取一般风险准备
                                                            桂林莱茵生物科技股份有限公司 2012 年半年度报告摘要3.对所有者(或股东)的分配4.其他(五)所有者权益内部结转1.资本公积转增资本(或股本)2.盈余公积转增资本(或股本)3.盈余公积弥补亏损4.其他(六)专项储备1.本期提取2.本期使用(七)其他
                             129,533 83,217,5               8,834,9        -9,988,8 -62,938. 211,739.7 211,746,14四、本期期末余额
                              ,760.00   30.86                 43.24           94.16      85          5       0.84上年金额
                                                                                                            单位: 元
                                                                上年金额
                                                归属于母公司所有者权益
             项目                                                                               少数股东 所有者权
                             实收资
                                    资本公 减:库存 专项储 盈余公 一般风 未分配                   权益     益合计
                             本(或                                                   其他
                                      积       股     备     积   险准备 利润
                             股本)
                             129,533 83,217,5               8,573,3        5,548,24             240,730.2 227,113,61一、上年年末余额
                              ,760.00   30.86                 42.24            9.49                     5       2.84
    加:同一控制下企业合并产生的追溯调整
    加:会计政策变更
           前期差错更正
           其他
                             129,533 83,217,5               8,573,3        5,548,24             240,730.2 227,113,61二、本年年初余额
                              ,760.00   30.86                 42.24            9.49                     5       2.84
    三、本期增减变动金额(减少                                 261,601         2,264,55 -158,14           2,361,631.
                                                                                            -6,377.00
    以“-”号填列)                                               .00             6.20    8.71                  49
                                                                           2,526,15                         2,519,780.
    (一)净利润                                                                                    -6,377.00
                                                                               7.20                                20
                                                                                      -158,14               -158,148.7(二)其他综合收益
                                                                                         8.71                        1
                                                                           2,526,15 -158,14           2,361,631.
    上述(一)和(二)小计                                                                      -6,377.00
                                                                               7.20    8.71                  49(三)所有者投入和减少资本1.所有者投入资本2.股份支付计入所有者权益的金额3.其他
                                                           261,601         -261,60(四)利润分配
                                                               .00            1.00
                                                           261,601         -261,601.提取盈余公积
                                                               .00            1.00
                                                           桂林莱茵生物科技股份有限公司 2012 年半年度报告摘要2.提取一般风险准备3.对所有者(或股东)的分配4.其他(五)所有者权益内部结转1.资本公积转增资本(或股本)2.盈余公积转增资本(或股本)3.盈余公积弥补亏损4.其他(六)专项储备1.本期提取2.本期使用(七)其他
                             129,533 83,217,5              8,834,9         7,812,80 -158,14 234,353.2 229,475,24四、本期期末余额
                              ,760.00   30.86                43.24             5.69    8.71         5       4.338、母公司所有者权益变动表本期金额
                                                                                                       单位: 元
                                                                本期金额
              项目            实收资本                                         一般风险 未分配利 所有者权
                                         资本公积 减:库存股 专项储备 盈余公积
                              (或股本)                                         准备     润     益合计
                              129,533,76 85,883,914                  8,834,943.            39,242,161 263,494,77一、上年年末余额
                                    0.00        .34                         24                    .94       9.52
    加:会计政策变更
           前期差错更正
           其他
                              129,533,76 85,883,914                  8,834,943.            39,242,161 263,494,77二、本年年初余额
                                    0.00        .34                         24                    .94       9.52
    三、本期增减变动金额(减少                                                                 -12,158,89 -12,158,89
    以“-”号填列)                                                                                 3.95       3.95
                                                                                           -12,158,89 -12,158,89(一)净利润
                                                                                                 3.95       3.95
    (二)其他综合收益                                                                                          0.00
                                                                                           -12,158,89 -12,158,89上述(一)和(二)小计
                                                                                                 3.95       3.95(三)所有者投入和减少资本1.所有者投入资本2.股份支付计入所有者权益的金额3.其他(四)利润分配1.提取盈余公积2.提取一般风险准备
                                                            桂林莱茵生物科技股份有限公司 2012 年半年度报告摘要3.对所有者(或股东)的分配4.其他(五)所有者权益内部结转1.资本公积转增资本(或股本)2.盈余公积转增资本(或股本)3.盈余公积弥补亏损4.其他(六)专项储备1.本期提取2.本期使用(七)其他
                               129,533,76 85,883,914                  8,834,943.         27,083,267 251,335,88四、本期期末余额
                                     0.00        .34                         24                 .99       5.57上年金额
                                                                                                       单位: 元
                                                                 上年金额
              项目             实收资本                                         一般风险 未分配利 所有者权
                                          资本公积 减:库存股 专项储备 盈余公积
                               (或股本)                                         准备       润   益合计
                                129,533,76 85,883,914                 8,573,342.         21,701,583 245,692,59一、上年年末余额
                                      0.00        .34                        24                 .25       9.83
    加:会计政策变更
           前期差错更正
           其他
                                129,533,76 85,883,914                 8,573,342.         21,701,583 245,692,59二、本年年初余额
                                      0.00        .34                        24                 .25       9.83
    三、本期增减变动金额(减少以                                                             17,540,578 17,802,179
                                                                     261,601.00
    “-”号填列)                                                                                  .69        .69
                                                                                         17,802,179 17,802,179(一)净利润
                                                                                                .69        .69(二)其他综合收益
                                                                                         17,802,179 17,802,179上述(一)和(二)小计
                                                                                                .69        .69(三)所有者投入和减少资本1.所有者投入资本2.股份支付计入所有者权益的金额3.其他
                                                                                          -261,601.0
    (四)利润分配                                                       261,601.00
                                                                                                   0
                                                                                          -261,601.0
    1.提取盈余公积                                                      261,601.00
                                                                                                   02.提取一般风险准备3.对所有者(或股东)的分配4.其他(五)所有者权益内部结转1.资本公积转增资本(或股本)2.盈余公积转增资本(或股本)
                                                       桂林莱茵生物科技股份有限公司 2012 年半年度报告摘要3.盈余公积弥补亏损4.其他(六)专项储备1.本期提取2.本期使用(七)其他
                               129,533,76 85,883,914             8,834,943.          39,242,161 263,494,77四、本期期末余额
                                     0.00        .34                    24                  .94       9.52(三)报表附注1、主要会计政策、会计估计的变更以及重大会计差错更正及其影响数(1)会计政策变更本报告期主要会计政策是否变更□ 是 √ 否(2)会计估计变更本报告期主要会计估计是否变更□ 是 √ 否(3)会计差错更正本报告期是否发现前期会计差错□ 是 √ 否2、合并报表合并范围发生变更的理由不适用。3、被出具非标准审计报告,列示涉及事项的有关附注不适用。
                                                                              董事长:姚新德
                                                             董事会批准报送日期:2012 年 08 月 27 日
数据加载中...
prevnext
手机查看股票